Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 32, Number 2—February 2026
Research Letter
Acute Severe Hepatitis B Virus Infection in Previously Vaccinated Patient during Acalabrutinib Treatment
Lukasz Rojek
, Tomasz Wnuk-Lipinski, Iwona Marek, Hubert Grabowski, and Krystian Adrych
, Tomasz Wnuk-Lipinski, Iwona Marek, Hubert Grabowski, and Krystian Adrych
Table 2
Virologic test results a case of severe HBV infection in previously vaccinated patient during acalabrutinib treatment*
| Test | Before starting acalabrutinib |
Acute hepatitis B† | After liver transplant‡ | |
|---|---|---|---|---|
| 2022 | 2023 | |||
| HBsAg | Undetectable | NA | Detectable | Undetectable |
| HBeAg |
NA |
NA |
Detectable |
NA |
| Anti-HBs, mIU/mL | 104 | 120.25 | 0 | 41.8 |
| Anti-HBc total antibodies | Undetectable | Undetectable | Detectable | Detectable |
| Anti-HBc IgM |
NA |
NA |
Detectable |
NA |
| HBV DNA, IU/mL | NA | NA | 1.67 ×107 | Undetectable |
*Anti-HBS, antibody to HBsAG; anti-HBc, antibody to HBcAG; HBcAg, hepatitis B core antigen; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not available. †February 2024. ‡September 2024.
Page created: January 29, 2026
Page updated: February 09, 2026
Page reviewed: February 09, 2026
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.